Citation: | DAN Liqin, ZHANG Zhonglin, LUO Zhigang. Value of serum insulin-like growth factor-1 levels in diagnosis and treatment of primary hyperthyroidism[J]. Journal of Clinical Medicine in Practice, 2024, 28(24): 73-76. DOI: 10.7619/jcmp.20243907 |
To explore the value of serum insulin-like growth factor-1 (IGF-1) levels in diagnosis and treatment of primary hyperthyroidism.
150 patients with primary hyperthyroidism (hyperthyroidism group) and 85 patients with hypothyroidism (hypothyroidism group) were selected as study subjects. During the same period, 60 healthy individuals were selected as control group. The levels of serum IGF-1, thyroid peroxidase antibody (TPOAb), thyroid stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), triiodothyronine (T3) and total thyroxine (T4) were measured in the three groups. The serum visfatin levels in the three groups were detected using an enzyme-linked immunosorbent assay. Multifactor Logistic regression analysis was used to screen for risk factors of primary hyperthyroidism.
The levels of IGF-1, FT3, FT4, T3 and T4 in the hyperthyroidism group were significantly higher than those in the hypothyroidism and control groups, while TSH levels were significantly lower (P < 0.05). TPOAb and visfatin levels in the hyperthyroidism group were significantly higher than those in the control group, but significantly lower than those in the hypothyroidism group (P < 0.05). The serum IGF-1 levels in patients with primary hyperthyroidism before and after 3 months of treatment were (60.11±7.23) and (30.23± 3.22) μg/L, respectively, showing a statistically significant difference (t=8.436, P < 0.001). Serum FT3, FT4, T3, T4, TPOAb, IGF-1 and visfatin levels increased and serum TSH levels decreased as risk factors for primary hyperthyroidism (P < 0.05).
The level of serum IGF-1 is closely related to thyroid function and may serve as an important reference indicator for the diagnosis and monitoring of the efficacy of primary hyperthyroidism treatment.
[1] |
LEE S Y, PEARCE E N. Hyperthyroidism: a review[J]. JAMA, 2023, 330(15): 1472-1483. doi: 10.1001/jama.2023.19052
|
[2] |
杨悦漪, 林霞, 王丽兵. 25-羟基维生素D、人β防御素-2及胰岛素样生长因子1水平与痤疮患者疾病严重程度的关系[J]. 实用临床医药杂志, 2024, 28(16): 60-64. doi: 10.7619/jcmp.20233195
|
[3] |
孟利军, 郭晓鹤, 董戴源, 等. 沙利度胺联合英夫利西治疗难治性炎症性肠病效果及对胰岛素样生长因子-1、转化生长因子-β1的影响[J]. 实用临床医药杂志, 2024, 28(1): 68-72, 77. doi: 10.7619/jcmp.20230274
|
[4] |
赵春慧, 宋光耀, 魏立民. 甲状腺相关疾病中IGF-1及其受体的表达及意义[J]. 医学综述, 2015(3): 412-414.
|
[5] |
MAHZARI M M, ALANAZI M M, ALABDULKAREEM Y M, et al. Efficacy of anti-thyroid medications in patients with Graves' disease[J]. BMC Endocr Disord, 2024, 24(1): 180. doi: 10.1186/s12902-024-01707-0
|
[6] |
闫园园, 魏剑芬, 李世超, 等. 血清胰岛素样生长因子-1与糖尿病合并甲状腺疾病的相关性[J]. 广东医学, 2019, 40(5): 647-651.
|
[7] |
王红梅, 姚韧寰, 赵予韬, 等. 探究甲亢患者情绪及睡眠状况及其与血清学指标的相关性[J]. 标记免疫分析与临床, 2022, 29(1): 19-22.
|
[8] |
杨建军, 毛利娜, 杨利, 等. 血清胰岛素样生长因子1与内脂素在甲状腺功能亢进患者中的变化及临床意义[J]. 标记免疫分析与临床, 2019, 26(12): 2096-2100.
|
[9] |
朱玉芳, 潘革. GH-IGF-1轴与儿童生长发育[J]. 医学综述, 2008, 14(3): 321-323.
|
[10] |
张林渊, 张金波, 陶永明, 等. 生长激素对多囊卵巢综合征患者体外受精-胚胎移植的影响[J]. 实用临床医药杂志, 2023, 27(4): 48-51. doi: 10.7619/jcmp.20222139
|
[11] |
孙成芝, 何成邦, 汪发莲. 血清转化生长因子阻、游离脂肪酸与甲亢肝损害患者氧化应激状态的相关性分析[J]. 标记免疫分析与临床, 2018, 25(9): 1364-1367.
|
[12] |
刘广钊, 何飞屏, 梁季鸿, 等. 甲状腺功能减退患者血清胰岛素样生长因子-1的变化及其意义[J]. 临床荟萃, 2000, 15(20): 916-918.
|
[13] |
罗英. 血清内脂素及脂联素联合检测在甲状腺结节良恶性诊断中的价值[J]. 川北医学院学报, 2020, 35(2): 309-312.
|
[14] |
谭丽艳, 杨震宇, 潘佳秋. 甲状腺功能异常患者血清内脂素水平的变化及其与甲状腺激素的关系[J]. 实用医学杂志, 2011, 27(19): 3532-3534.
|
[15] |
邢琪, 常文龙, 翟娜. 甲状腺功能亢进症患者血清果糖胺、糖化血红蛋白水平及其与糖代谢指标水平的相关性[J]. 检验医学与临床, 2024, 21(15): 2168-2171.
|